The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-21

Study Completion Date

2020-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to compare the gut microbiota and clinical outcomes of oral FMT during antibiotic treatment, immediately following antibiotic treatment, and placebo. The second objective is to assess the safety and feasibility of daily oral Fecal Microbiome Transplant (FMT) as a treatment option.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gut Microbiota Changes After Fecal Microbiota Transplantation

NCT02557685

Clostridium Difficile Infection

UNKNOWN PHASE2

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445

Clostridium Difficile Infection Recurrence

TERMINATED PHASE2

Mucosal Versus Fecal Microbiota in FMT

NCT02133651

Clostridium Difficile

COMPLETED

Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea

NCT02801656

Clostridium Difficile

WITHDRAWN PHASE3

Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection

NCT03427229

Clostridium Difficile Pseudomembranous Colitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clostridium difficile is the most frequent bacterial cause of antibiotic-associated diarrhea. Those with a previous C. difficile infection (CDI) are at high risk of recurrent infection. Recurrent CDI often occurs when the normal gut microbiota are disrupted. Dysbiosis of the gut microbiota predisposes to CDI which, despite treatment can recur in 30% of patients. A novel way to prevent CDI recurrence is by instilling feces from a healthy individual into the intestine of the CDI patient, thereby restoring balance in the gut microbiota. However, it is unknown whether or not fecal microbiota transplantation (FMT) is an efficacious choice for CDI recurrence prevention when used concurrently with antibiotics. We propose a pilot randomized, double-blind placebo controlled trial comparing oral FMT with placebo in patients with a history of CDI, currently undergoing antibiotic treatment. We will collect fecal samples from subjects prior to, during, and after FMT and collect metagenomics and microbiologic data on microbiota composition and function, and CDI recurrence. The trial's primary outcome is gut microbial composition and function. Secondary outcomes are feasibility and safety, and recurrent CDI during the trial period. In this 3 group study, FMT will be administered daily via oral capsules containing frozen fecal microbiota from universal donors in group 1, administered at the end of antibiotic treatment for group 2, and group 3 will receive daily placebo. The results of this study will provide the necessary pilot data to examine whether or not concurrent FMT in antibiotic treated patients who are at high risk for recurrent CDI can maintain a diverse healthy GI microbiota.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clostridium Difficile Infection C.Difficile Diarrhea CDI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a phase 2, double-blind, randomized, placebo-controlled trial assessing the effects of either daily (group 1) or one-time (group 2) oral FMT on the composition and function of gut microbiome compared to placebo (group 3) in a population of patients with a history of Clostridium difficile infection (CDI).

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose FMT Capsule DE

FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic

Group Type EXPERIMENTAL

Low Dose FMT Capsule DE

Intervention Type DRUG

5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.

Single dose FMT Capsule DE

FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.

Group Type ACTIVE_COMPARATOR

Single Dose FMT Capsule DE

Intervention Type DRUG

30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.

Placebo Oral Capsule

Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic

Group Type PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type DRUG

Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low Dose FMT Capsule DE

5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.

Intervention Type DRUG

Single Dose FMT Capsule DE

30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.

Intervention Type DRUG

Placebo oral capsule

Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FMT Capsule DE FMT Capsule DE Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Cognitively intact and willing to provide informed consent
2. Willing and able to comply with all study procedures for the duration of the study
3. Able to take oral medications
4. Age 18 or over
5. Recent CDI episode occurring in the last 180 days with completion of therapy as confirmed by the electronic medical record (EMR)
6. Receiving antibiotics at enrollment for reasons other than CDI and having taken the antibiotics for no longer than 10 days.
7. Women of childbearing potential in a sexual relationship with men must use an acceptable method of contraception (including, but not limited to, barriers with additional spermicidal foam or jelly, intrauterine devices, hormonal contraception started at least 30 days before enrollment into the study, or intercourse with men who underwent a vasectomy) for 4 weeks following completion of the study treatment,
8. Males must agree to avoid impregnation of women during and for 4 weeks following completion of the study treatment.
9. Able to take the test capsule successfully with no signs or symptoms of dysphagia.

Exclusion Criteria

1. Females who are pregnant, lactating, or planning to become pregnant during the study. Female patients of childbearing potential will take a pregnancy test at the intervention visit and will be excluded if pregnant.
2. Inability (e.g. dysphagia) to or unwilling to swallow capsules
3. Known or suspected toxic megacolon and or known small bowel ileus
4. Bowel obstruction or other gut motility issues occurring in the last two weeks taht are unresolved as noted by the patient or in the EMR
5. Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment not including appendectomy or cholecystectomy.
6. History of bariatric or colectomy surgery
7. Concurrent intensive induction chemotherapy, radiation therapy, or biologic treatment for an active malignancy. Patients on maintenance chemotherapy may be enrolled after consultation with the medical monitor.
8. Expected life expectancy less than 6 months.
9. Patients with severe anaphylactic or anaphylactoid food allergy.
10. Solid organ transplant recipients ≤90 days post-transplant or on active treatment for rejection
11. Neutropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-tumor necrosis factor (TNF) will be permitted. Patients on monoclonal antibodies to B and T cells, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhibitors (tacrolimus, cyclosporine), and mycophenolate mofetil may only be enrolled after consultation with the medical monitor.
12. At risk of CMV/EBV associated disease, negative immunoglobulin gamma (IgG) testing for cytomegalovirus (CMV) or Epstein Barr Virus (EBV)
13. Any other gastrointestinal illness including diarrhea
14. On oral vancomycin or metronidazole
15. Having been taking the currently prescribed antibiotic for over 10 days
16. Any condition that would jeopardize the safety or rights of the patient, would make it unlikely for the patient to complete the study, or would confound the results of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No